Literature DB >> 17332616

Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy.

Lieselot Brepoels1, Sigrid Stroobants, Peter Vandenberghe, Karoline Spaepen, Patrick Dupont, Johan Nuyts, Guy Bormans, Luc Mortelmans, Gregor Verhoef, Christiane De Wolf-Peeters.   

Abstract

UNLABELLED: To be a reliable predictor of response, (18)F-FDG uptake should reflect changes in the amount of viable tumor cells. However, (18)F-FDG also accumulates in inflammatory cells. Shortly after treatment, the influx of inflammatory cells in the tumor can therefore interfere with early response evaluation. The aim of this study was to investigate whether this inflammation is suppressed by the administration of corticosteroids and, in turn, can improve the correlation of (18)F-FDG uptake with tumor cell kill.
METHODS: Severe combined immunodeficiency mice were inoculated subcutaneously with Daudi cells. When the tumor measured 15 mm, mice were divided in 2 groups treated with 1 single dose of cyclophosphamide, 125 mg/kg (group A) or cyclophosphamide followed by hydrocortisone (0.2 mg/d) for 5 d (group B). The change in (18)F-FDG uptake was evaluated with small-animal PET (5 mice/group) on D+6, D+9, D+13, and D+16 (days after treatment). At each time point, 4 mice per group were sacrificed for quantification of the different tumor cell fractions by flow cytometry and histopathology. Changes in (18)F-FDG uptake were correlated with inflammation and viable tumor cells.
RESULTS: Cyclophosphamide administration resulted in a steady reduction in viable cell fraction until D+9 (reduction from baseline, -64%). The viable cell fraction increased again on D+13. A transient influx of inflammatory cells was seen from D+6 to D+13 (peak on D+9, 24% of total cell fraction). After hydrocortisone administration, a similar reduction in the viable cell fraction was seen. The inflammatory response was less pronounced but developed with earlier kinetics (peak on D+6 [15% of total cell fraction], almost resolved on D+9) and consisted primarily of granulocytes instead of mononuclear cells in the absence of corticosteroids. In both groups, a significant reduction in (18)F-FDG uptake was seen until D+6. On D+9, a transient increase in (18)F-FDG uptake was seen in group A, whereas a further decrease was observed in group B.
CONCLUSION: After corticosteroid administration, the contribution of inflammatory cells to the (18)F-FDG uptake was less important than that in mice treated with chemotherapy alone. The earlier, but weaker, inflammatory response after corticosteroid administration consists primarily of granulocytes instead of mononuclear cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332616

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET.

Authors:  Lieselot Brepoels; Marijke De Saint-Hubert; Sigrid Stroobants; Gregor Verhoef; Jan Balzarini; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-12       Impact factor: 9.236

2.  Usefulness of automatic quantification of immunochemical staining on whole tumor sections for correlation with oncological small animal PET studies: an example with cell proliferation, glucose transporter 1 and FDG.

Authors:  Nicolas Aide; Alexandre Labiche; Paulette Herlin; Maria Paciencia; Laurent Poulain; Soizic Dutoit; Françoise Montravers; Pascal Gauduchon; Jacques Chasle
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

3.  Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours.

Authors:  Huaijun Wang; Junjie Li; Feng Chen; Frederik De Keyzer; Jie Yu; Yuanbo Feng; Johan Nuyts; Guy Marchal; Yicheng Ni
Journal:  Eur Radiol       Date:  2010-02-25       Impact factor: 5.315

4.  Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT.

Authors:  Bowen Shi; Huimin Lin; Miao Zhang; Wei Lu; Ying Qu; Huan Zhang
Journal:  J Vis Exp       Date:  2018-01-22       Impact factor: 1.355

5.  Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging.

Authors:  Marijke De Saint-Hubert; Huijun Wang; Ellen Devos; Kathleen Vunckx; Lin Zhou; Chris Reutelingsperger; Alfons Verbruggen; Luc Mortelmans; Yicheng Ni; Felix M Mottaghy
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

6.  Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma.

Authors:  Marijke De Saint-Hubert; Ellen Devos; Abdelilah Ibrahimi; Zeger Debyser; Luc Mortelmans; Felix M Mottaghy
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10

7.  Molecular imaging of therapy response with (18)F-FLT and (18)F-FDG following cyclophosphamide and mTOR inhibition.

Authors:  Marijke De Saint-Hubert; Lieselot Brepoels; Ellen Devos; Peter Vermaelen; Tjibe De Groot; Thomas Tousseyn; Luc Mortelmans; Felix M Mottaghy
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

8.  Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.

Authors:  Marius E Mayerhoefer; Markus Raderer; Ulrich Jaeger; Philipp Staber; Barbara Kiesewetter; Daniela Senn; Ferdia A Gallagher; Kevin Brindle; Edit Porpaczy; Michael Weber; Dominik Berzaczy; Ingrid Simonitsch-Klupp; Christian Sillaber; Cathrin Skrabs; Alexander Haug
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-26       Impact factor: 9.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.